MIT engineers recruit microbes to help fight cholera

Probiotic bacteria can diagnose, prevent, and treat infections.


MIT engineers have developed a probiotic mix of natural and engineered bacteria to diagnose and treat cholera, an intestinal infection that causes severe dehydration.

Cholera outbreaks are usually caused by contaminated drinking water, and infections can turn fatal if not treated. The most common treatment is rehydration, which must be done intravenously if the patient is extremely dehydrated. However, intravenous treatment is not always available to patients who need it, and the disease kills an estimated 95,000 people per year.

The MIT team’s new probiotic mix could be consumed regularly as a preventative measure in regions where cholera is common, or used to treat people soon after infection occurs, says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering.

“Our goal was to use synthetic biology to develop an inexpensive means to detect and diagnose as well as suppress or treat cholera infections,” says Collins, who is the senior author of the study. “If one could inexpensively and quickly track the disease and treat it with natural or engineered probiotics, it could be a game-changer in many parts of the world.”

The lead authors of the paper, which appears in the June 13 issue of Science Translational Medicine, are former Boston University graduate student Ning Mao, MIT postdoc Andres Cubillos-Ruiz, and former MIT postdoc D. Ewen Cameron.

Detection and treatment


To create their “living diagnostic” for cholera, the researchers chose a strain of bacteria called Lactococcus lactis, which is safe for human consumption and is used in the production of cheese and buttermilk.

They engineered into this bacterium a genetic circuit that detects a molecule produced by Vibrio cholerae, the microbe that causes cholera. When engineered L. lactis encounters this molecule, known as CAI-1, it sets off a signaling cascade that turns on an enzyme called beta-lactamase. This enzyme produces a red color that can be detected by analyzing stool samples. This process now takes several hours, but the researchers hope to shorten that time.

The researchers had hoped to further engineer L. lactis so that it could treat or prevent cholera infections. They began by engineering the microbes to produce antimicrobial peptides that could kill V. cholerae, but they eventually found that the peptides were being rendered harmless after being secreted by the cells.

Serendipitously, however, the team discovered that unmodified L. lactis can actually kill cholera microbes by producing lactic acid, a natural byproduct of their metabolism. Lactic acid makes the gastrointestinal environment more acidic, inhibiting the growth of V. cholerae.

The engineered version of L. lactis does not produce enough lactic acid to kill cholera microbes, so the researchers combined the engineered bacteria with the unmodified version to create a probiotic mixture that can both detect and treat cholera. In tests in mice, the researchers found that this probiotic mixture could successfully prevent cholera infections from developing and could also treat existing infections.

Alternatives to antibiotics


Collins says he anticipates that the probiotic, which could be incorporated into a pill or a yogurt-like drink, could be used either as a preventative measure or for treating infections once they begin. Having the ability to diagnose cholera easily could also help public health officials detect outbreaks earlier and monitor the spread of the disease.

“I am particularly excited about this study because it presents a series of far-reaching, practical possibilities as well as scientific advances,” says Matthew Chang, an associate professor of biochemistry at the National University of Singapore, who was not involved in the research.

“For instance, this work certainly enables us to envision the direct use of probiotics in combination with their modified forms for the surveillance and prevention of cholera,” Chang says. “Even further, many can leverage this study, in particular its generalizable ‘sense-and-respond’ approach, to devise various diet-based prophylactic strategies against other communicable infectious diseases.”

The MIT team is now exploring the possibility of using this approach to combat other microbes, such as Clostridium difficile, which causes gastrointestinal infections, and bacteria known as enterococci, which can cause many types of infections.

“There is emerging interest in using probiotics to treat disease, largely from the growing recognition of the microbiome and the role it plays in health and disease, and the pressing need to find alternatives to antibiotics,” Collins says.

The research was funded by the Defense Threat Reduction Agency, the Gates Foundation, and the Paul G. Allen Frontiers Group.

Featured Research

Model helps robots navigate more like humans do

In simulations, robots move through new environments by exploring, observing, and drawing from learned experiences. When moving throu...



AC Investment Group Key Financial & Operational Data (Quarterly)*

(million $)
Q117
Q417Q118YoY%QoQ%
Revenues5,0534,6664,76217.5%2.0%
EBITDA**1,4001,7392,02244.4%16.3%
EBITDA margin34.5%37.3%42.5%8.0pp5.2pp
Net income4,502,164,019.2%132.0%
Capex5,711,8071,2126.1%(60.1%)
AC Invest Jersey3,53,673,34.2%1.6%
AC Invest London5,05,25,1(0.6%)(0.2%)
*Based on figures prepared by IFRS;
**EBITDA is a non-GAAP financial measure.


We invest in high tech companies.*



DialPad Flatiron Health Stripe Acalvio Editas Medicine Foundation Medicine




(Investments $)20172018
Technology
14,286
17,632
Consumer
4,620
6,228
Life Science
3,2
3,5
Data and AI
1,492
1,979
Enterprise
3,495
4,090
Robotics
3,5
3,6
Health
5,01
5,02


Our companies push the edge of what’s possible.





We help build successful companies.



Board of Directors Investor Relations and Financials

Our story.







2017
Launched as A/C Investment in 2017, A/C is the venture capital arm of AC ADV Inc. A/C has $112 million under management with 42 investments




2018
A/C Invest built a team of world-class economists, physicians, scientists, marketers, and investors who work together to provide these startups exceptional support on the road to business shift.

Adem Çetinkaya

Adem Çetinkaya Yatırım A.Ş. adem çetinkaya faiz oranlı swap ve açık piyasa işlemleri adem çetinkaya venture capital işlemleri yapılmaktadır. Adem Çetinkaya finansal swap riskinin hesaplanması ve azaltılmasında tezgah üstü piyasa işlmleri kullanılmaktadır.Cambridge, London ve Jersey adasında çoğunlukla devlet kurumları ve uluslararası şirketler adına swap ve offshore yatırım işlemleri yapmaktadır.Faiz oranlı swap işlemlerinin yapılandırılması, değiştirilmesi ve sonlandırılması ile faiz oranlı takasların opsiyon temelli özelliklerinde caps ve floor gibi ilgili finansal risklerin tespit edilerek yönetilmesi gerekm Offshore piyasası uluslararası yatırımlar için fırsatlaAr yaratsa da, offshore işlemlerde mali suçların önlenmesi ve uluslararası regülasyonların gözetilmesi gerekmektedir. ektedir.
TALK TO US
Feel free to drop us a line to contact us
CETINKAYA INVESTMENT INC
301 Massachusetts Avenue Cambridge, MA 02139